SABS

News

globenewswire.comSAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meetingglobenewswire.comMay 29

marketbeat.comSAB Biotherapeutics Q1 Earnings Call Highlightsmarketbeat.comMay 12

globenewswire.comSAB BIO Reports Q1 2026 Financial Results and Recent Business Highlightsglobenewswire.comMay 12

globenewswire.comSAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ETglobenewswire.comMay 5

globenewswire.comSAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026globenewswire.comApr 22

Trade SABS

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing immunotherapies built upon human antibodies. The company leverages sophisticated genetic engineering and antibody research to cultivate specialized transchromosomic bovine herds. These unique animals are engineered to generate fully human antibodies, which are then directed against a variety of specific ailments. This broad scope includes infectious diseases such as COVID-19 and influenza, various immune and autoimmune conditions like type 1 diabetes, and potential applications in organ transplantation and cancer treatment. Central to their strategy is the proprietary DiversitAb immunotherapy platform, which yields wholly human polyclonal antibodies, thereby circumventing the need for human donors. Key assets in their clinical pipeline feature SAB-185, a fully human polyclonal antibody therapeutic currently undergoing Phase III trials for COVID-19, and SAB-176, another fully human polyclonal antibody in development for the prevention or treatment of severe influenza. Additionally, their preclinical portfolio contains SAB-142, intended for autoimmune disorders such as type 1 diabetes and for managing organ transplant induction/rejection. Established in 2014, SAB Biotherapeutics is based in Sioux Falls, South Dakota.

CEO: Samuel J. Reich
IPO Date: Feb 9, 2021

Market Data

Open: $3.93
High: $4.10
Low: $3.85
Volume: 2.4M
Avg Volume: 803.5K
52W High: $6.60
52W Low: $1.67

Valuation

Market Cap: $38M
Enterprise Value: $24M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-46M
Revenue: $0
Net Income: $13M
Cash: $11M
Debt: $6.0M

Events

EarningsAug 6

EPS est. -0.29